Male Pattern Hair Loss

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
MERCK
PROPECIA® (finasteride) 1mg This site is intended only for healthcare professionals of the United States,
its territories, and Puerto Rico. Non-US residents click here. 		 PROPECIA Packaging
Home Prescribing Information Patient Product Information Patient Website
Product Data and Highlights
Highlights of Clinical Studies
Clinical Hair Count Results
Photographic Assessment
Patient Self-Assessment
Investigator Assessment
Hair Weight Results
Selected Safety Information
How PROPECIA Works
Study Design
Prescribing PROPECIA
Resources
5-Year Data
See the results of the longest reported controlled clinical study of male pattern hair loss.
View study results.
 
Patient Self-Assessment

In the longest reported controlled clinical study of male pattern hair loss patients ever conducted ...

Patients reported success with PROPECIA® (finasteride)1
Patients treated with PROPECIA reported significant improvement in satisfaction with appearance at 5 years, according to patient questionnaires.
Percentage of Patients Improved Percentage of Patients Improved

Adapted from Kaufman KD et al1 with permission from John Libbey Eurotext.
 
Investigators reported success with PROPECIA
 
At 5 years, investigators rated 77% of men treated with PROPECIA as having increased hair growth compared with 15% of men treated with placebo.
 
Important Information About PROPECIA
 
PROPECIA is the first oral therapy indicated for the treatment of male pattern hair loss in MEN ONLY. Safety and efficacy were demonstrated in men, aged 18 to 41, with mild to moderate hair loss of the vertex and anterior mid-scalp area. Efficacy in bitemporal recession has not been established.
 
PROPECIA is not indicated in women or children.
 
Women should not handle crushed or broken PROPECIA tablets when they are pregnant or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus. PROPECIA tablets are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets have not been broken or crushed.
 
Physicians should instruct their patients to promptly report any changes in their breasts such as lumps, pain, or nipple discharge. Breast changes including breast enlargement, tenderness, and neoplasm have been reported.
 
In postmarketing experience, the following adverse events have been reported: breast tenderness and enlargement; hypersensitivity reactions including rash, pruritus, urticaria, and swelling of the lips and face; and testicular pain.
 

    PROPECIA is a registered trademark of Merck & Co., Inc.
20753248(2)-12/07–PRP